Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 63
Healthy volunteers: no

Brief summary:
This is a study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-8666 in participants with type 2 diabetes mellitus (T2DM). Participants enrolled in this trial would be either treatment-naive or have washed off of oral anti-hyperglycemic agents. MK-8666 is planned to be administered orally for up to 2 weeks. The primary hypothesis for this study is that after 14 days of once daily treatment with MK-8666, at a dose that is safe and well tolerated, the placebo-corrected fasting plasma glucose reduction from baseline is ≥34 mg/dL.

Detailed description:

Arms:
arm 1: MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14. arm 2: MK-8666, 150 mg, oral, QD, for Days 1 to 14 arm 3: MK-8666, 500 mg, oral, QD for Days 1 to 14 arm 4: Placebo, oral, QD for Days 1 to 14

Interventions: intervention 1: MK-8666 intervention 2: Placebo
Intervention descriptions: intervention 1: MK-8666, capsules, oral, QD, Days 1 to 14 intervention 2: Placebo, capsules, oral, QD, Days 1 to 14

Protocol document: